CD19 and post-transplant lymphoproliferative disease: Though anti-CD19 CAR T-cell therapy might offer an opportunity for PTLD patients, sizable clinical trials evaluating the safety and efficacy of this novel cell therapy against PTLD are lacking, and, to date, only a few cases, primarily in the setting of SOT have been reported [66,67,68].